Article Text

Download PDFPDF
Incidence of Parkinson’s disease in Norway: the Norwegian ParkWest study
  1. G Alves1,2,
  2. B Müller3,8,
  3. K Herlofson4,
  4. I HogenEsch5,
  5. W Telstad6,
  6. D Aarsland1,7,8,
  7. O-B Tysnes3,8,
  8. J P Larsen1,2,8
  1. 1
    The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway
  2. 2
    Department of Neurology, Stavanger University Hospital, Stavanger, Norway
  3. 3
    Department of Neurology, Haukeland University Hospital, Bergen, Norway
  4. 4
    Department of Neurology, Sørlandet Hospital, Arendal, Norway
  5. 5
    Department of Neurology, Haugesund Hospital, Haugesund, Norway
  6. 6
    Department of Neurology, Central Hospital of Sogn and Fjordane, Førde, Norway
  7. 7
    Department of Psychiatry, Stavanger University Hospital, Stavanger, Norway
  8. 8
    School of Medicine, University of Bergen, Bergen, Norway
  1. Dr G Alves, The Norwegian Centre for Movement Disorders, Stavanger University Hospital, PO Box 8100, N-4068 Stavanger, Norway; algu{at}


Objective: To present the incidence of Parkinson’s disease (PD) in Norway and to explore gender influences on incidence and age at onset, as well as severity and pattern of parkinsonism at the time of diagnosis in a representative drug naïve cohort with newly diagnosed PD.

Methods: In four Norwegian counties comprising a base population of 1 052 075 inhabitants, multiple sources of case ascertainment and a four step diagnostic procedure were used to establish a representative cohort of patients with incident PD at a high level of diagnostic accuracy. Of a total of 604 subjects referred to the study, 265 individuals fulfilled the clinical research criteria of PD at their latest clinical visit, at a mean 28 months after identification.

Results: The incidence of PD in the study area, age standardised to the 1991 European standard population, was 12.6/105yr-1 (95% CI 11.1 to 14.2). The overall age standardised male to female ratio was 1.58 (95% CI 1.22 to 2.06), with a consistent male preponderance throughout all age groups. Clinical onset of PD was later in women than in men (68.6 vs 66.3 years; p = 0.062) whereas severity and pattern of parkinsonism in drug naïve patients was not different between genders at the time of diagnosis.

Conclusion: Incidence rates of PD in Norway are similar to those in other Western European and American countries. Female gender was associated with a considerably lower risk of PD and slightly delayed motor onset but had no impact on severity of parkinsonism or clinical phenotype in incident drug naïve PD, suggesting that the female gender influences on the nigrostriatal system are most pronounced in the preclinical phase of the disease.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • * Details of the Norwegian ParkWest study group can be found in the appendix.

  • Funding: The Norwegian ParkWest study was funded by the Western Norway Regional Health Authority (grant No 911218) and the Research Council of Norway (grant No 177966).

  • Competing interests: None.

  • Ethics approval: The study was approved by the Regional Committee for Medical and Health Research Ethics, Western-Norway, University of Bergen, Bergen, Norway.